Investors looking to capitalize on the artificial intelligence theme are increasingly weighing companies that are tied to AI-driven innovation but still face business headwinds. Recursion Pharmaceuticals and Fiverr both operate in AI-influenced markets, yet their stocks have endured substantial declines, reflecting skepticism about execution—especially at the clinical and revenue levels.
Key takeaways
- Recursion Pharmaceuticals faces ongoing development risk as it has no approved or late-stage products, even as its AI platform aims to improve drug development success rates.
- Fiverr has struggled with a softer revenue trend and fewer active buyers, though profitability improved on an earnings per share basis in the latest reported period.
- Common catalyst: progress that validates the business model—clinical and regulatory milestones for Recursion, and sustained platform engagement and spending improvements for Fiverr.
- Investor implication: both names look more suited to higher-volatility, longer-horizon investors rather than those seeking near-term certainty.
What Recursion Pharmaceuticals is betting on
Recursion Pharmaceuticals is a biotech company that uses an AI-powered approach to drug discovery. The company’s model centers on continuously running virtual experiments to identify candidate molecules for clinical trials, with the goal of improving the odds that early-stage compounds ultimately reach market.
The underlying market backdrop is the high cost and long timelines associated with developing new medicines. Recursion’s thesis is that AI can help counter the industry’s “Eroom’s law” challenge by selecting better candidates earlier—potentially leading to faster launches, stronger margins, and improved profitability if successful.
However, the key constraint for shareholders is that the company has not yet produced tangible validation at the product level. Recursion has no approved products and none in late-stage studies, leaving investors dependent on future clinical and regulatory outcomes rather than demonstrated commercialization.
The company’s strategy also faces intense competitive pressure. Larger pharmaceutical companies with greater resources are already incorporating AI into their own R&D workflows, including efforts that seek to replicate similar efficiencies on a broader scale.
One specific development program cited for potential upside is REC-4881, being developed for familial adenomatous polyposis (FAP), a rare condition that typically leads to precancerous gastrointestinal polyps and, eventually, colorectal cancer. The company has said clinical trial results showed a significant reduction in polyp burden. If REC-4881 advances meaningfully toward approval, it could strengthen confidence in Recursion’s platform and, in turn, support a rerating of the shares.
Still, clinical and regulatory execution risk remains central. Any setbacks in trial design, endpoints, safety, or review timelines could weigh on sentiment, especially given the company’s early-stage position.
Fiverr’s turnaround plan and the AI-related headwinds
Fiverr operates a freelance services marketplace that matches clients with service providers. The company initially benefited as businesses sought ways to buy AI-related services without hiring full specialist teams of researchers and engineers. Yet Fiverr’s broader financial picture has been pressured by declining revenue and falling active buyers.
Management’s response is to shift Fiverr’s positioning toward more complex work—projects that may be harder to complete through AI tools alone. The company also aims to raise both engagement and spend per buyer by attracting clients seeking larger, multi-step engagements rather than small, one-off tasks.
This strategic change is significant for the business model. Fiverr’s name traces back to a starting price of $5 for many early services. The current plan, according to the company, is to lean into the growth of projects priced around $1,000 and above, reflecting a move upmarket in terms of buyer needs and project complexity.
While revenue has moved down, the article notes that Fiverr’s net income improved during the first period referenced, with earnings per share reported at $0.23 versus $0.02 in the year-ago period. That profitability improvement provides some support for the idea that cost discipline and operating efficiency may be helping offset weaker top-line momentum.
Even so, the risks remain. The freelance marketplace is being reshaped by AI adoption: businesses increasingly use AI to perform tasks that previously would have required human freelancers. That dynamic could keep reducing demand for certain categories of work unless Fiverr’s higher-complexity focus gains traction. The company’s success will likely depend on whether larger projects can steadily attract buyers and sustain repeat usage.
In the meantime, investors will be watching for evidence that the strategy change can reverse the decline in active buyers and stabilize revenue—metrics that are directly tied to marketplace liquidity and growth.
Market reaction: why both stocks remain high-conviction but high-risk
Both Recursion and Fiverr are positioned at points in their respective value chains where expectations can swing quickly. For Recursion, the market’s patience is partly rooted in whether AI can deliver clinical differentiation quickly enough to matter. With no approved products to date, the stock’s trajectory is likely to remain sensitive to trial progress and regulatory signals.
For Fiverr, the market is effectively asking whether the platform can reaccelerate growth by evolving beyond simpler gigs and differentiating through projects that AI cannot easily replicate. While profitability improved in the referenced quarter, investors typically require consistent improvements in engagement and revenue to sustain a longer-term recovery narrative.
What to watch next
For Recursion, investors should focus on forthcoming clinical updates and any regulatory progress that could validate the AI-driven selection strategy, particularly around programs like REC-4881. For Fiverr, the key watch items are trends in active buyers and revenue, alongside evidence that the higher-complexity positioning is translating into stronger engagement and spending. Near-term market attention will also likely track broader AI sentiment and the impact of interest-rate expectations on risk appetite for unprofitable or turnaround-bound growth stocks.
